Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?
This article was originally published in PharmAsia News
The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence
You may also be interested in...
The European pharma trade group also plans communication offensive on health technology assessment as Japan reconsiders pricing methodology.
Japan's MHLW and Finance Ministry face off on the steps needed to shave reimbursement costs.